By Editorial TeamHealthcare’s finally moving away from its reactive, episodic model. This isn’t some small adjustment, it’s being completely rebuilt by AI-native companies that are designing preventive care from scratch and changing the entire economic model. If you’re an investor, you have to understand exactly how these startups use AI to get more people into the clinical funnel earlier while making sure there’s a clear way to get paid for it.
The Economics Driving AI-Guided Prevention
For years, preventive medicine couldn’t get off the ground because of basic patient behavior and, more importantly, because the economic incentives were all wrong. The fee-for-service world pays for procedures, not for good outcomes, which naturally pushes the system toward late-stage diagnostics and expensive treatments instead of proactive health. Think about it: our standard diagnostic tools are expensive, need a specialist to run them, and are stuck in big hospitals. This creates huge backlogs and limits who can even get checked. The result is we find diseases late, when treatment is more expensive and doesn’t work as well. AI-native companies are breaking this model by shifting the focus from one-off, reactive tests to continuous, AI-powered guardrails. By putting smart systems closer to the patient (sometimes right in their home or local clinic), these companies open up access to early detection and risk scoring for everyone, pulling more people into the top of the clinical funnel. The algorithm itself isn’t the whole story. What matters is how that algorithm gets built into a full platform that accounts for the real-world pressures of reimbursement, regulation, and what buyers will actually pay for. Investors need to stop looking at just the AI and start asking how a company’s product fits into the messy, evolving reality of healthcare.
New Diagnostics: Pushing Care Earlier and Cheaper
The AI-native companies that really stand out in prevention are the ones using their tech to move complex diagnostics out of the specialist’s office and into cheaper, more accessible places. This approach improves patient health and creates real economic savings. Take Caption Health, which is now part of GE HealthCare. Their AI platform, Caption Guidance, got FDA clearance for Caption Guidance to let any trained medical professional, not just a specialized sonographer, capture good cardiac ultrasound images. This is a perfect example of a truly AI-native company where the AI isn’t an add-on. It’s the foundation of the product, the data pipeline, and the business model. Caption Health is moving a complex procedure from the cardiology lab into primary care offices and remote clinics, which means heart problems can be found much sooner. Finding a problem earlier can mean a less invasive and far less expensive treatment later. It just makes sense. Viz.ai is another good example of using AI to speed up diagnosis and triage for critical events like strokes. While you might not call it “preventive” in the classic sense, their platform cuts down diagnostic delays, a huge part of effective early intervention. They’ve even shown they can accelerate clinical trial enrollment Viz.ai clinical trial enrollment acceleration rates by finding eligible patients faster with AI, proving the system-wide efficiencies you can get. By finding at-risk patients quickly and getting them into care, Viz.ai’s platform acts as a guardrail, stopping conditions from spiraling into more severe and costly states. These companies are building platforms that fit right into existing clinical workflows and generate the real-world evidence (RWE) needed to make a strong case to both the FDA and payers. Their success is built on getting through regulatory gates like 510(k) clearance and, critically, locking in CPT codes so they can get paid.
Getting Paid: The Reality of Reimbursement for Preventive AI
For an AI-native prevention company, proving your tech works in a clinical trial is one thing. Actually getting paid for it’s another battle entirely, and that’s where market forces really shape what gets built. Investors have to dig into a startup’s strategy for dealing with payers and see how they plan to fit into reimbursement models that are constantly changing. The new CMS guidelines on Remote Physiologic Monitoring (RPM) and Remote Therapeutic Monitoring (RTM) are a huge opportunity here. These codes create a way to bill for the continuous monitoring of chronic conditions outside of a hospital or clinic. So, an AI platform that uses these codes to provide smart, continuous oversight, and sends early warnings when a patient’s health is getting worse, is positioned to grab a lot of market share. Imagine an AI platform monitoring patients with early-stage heart disease through their wearables. If that platform’s AI alerts can be shown to reduce hospital visits or other bad outcomes, it fits perfectly into value-based care contracts and can bill using those RPM/RTM codes. The move from one-off, reactive appointments to continuous, AI-driven management is becoming an economic necessity. Even in a different area like pathology, Paige AI (now part of Tempus) shows this same principle of using AI to expand early detection. Their platform helps pathologists find subtle signs of cancer faster and with more accuracy, speeding up the diagnosis. A faster diagnosis means the patient starts treatment sooner, which improves their chances and can lower the total cost of care by catching the cancer at an earlier, more treatable stage. Because their AI is built to fit into existing lab workflows and show clear efficiency gains, it becomes a powerful tool for earlier intervention.
Investor Takeaway: It’s Not About the Algorithm
When VCs and other investors are looking at the next wave of preventive health startups, they need to look past the AI model’s technical specs. A good data moat and solid algorithms are just the table stakes. The real test is whether a company can turn its AI into actual economic value inside the current healthcare system. Look for startups that:
- Widen the clinical funnel: Does their AI actually move diagnostics or monitoring to earlier, cheaper settings for more people?
- Have a believable plan to get paid: Do they have FDA clearance (like a 510(k) or De Novo) and, most importantly, a path to a CPT code or a way to bill under existing structures like RPM/RTM? CMS guidelines on Remote Physiologic Monitoring
- Follow the clinical rules: Is there published proof it works? Is the model trained on real patient outcome data and built using standards like GMLP (Good Machine Learning Practice) to make sure it’s safe?
- Fit into the real world: Is this product a pain for doctors to use (a bolt-on that creates more work), or is it built to actually make their workflow more efficient?
The real-world pressures of getting paid, passing regulatory hurdles, and convincing people to buy your product are what drive development in healthcare. The winning AI-native prevention companies will be the ones that design their entire system around these pressures, building products that work clinically and also make financial sense at scale. This playbook is based on a close reading of regulatory filings, health economic models, and years of watching the AI in healthcare space evolve. It’s how you spot the AI-native companies with real potential.
Frequently Asked Questions
How do AI-native preventive healthcare companies address the historical economic disincentives for preventive medicine?
AI-native companies overcome historical economic disincentives by shifting from reactive diagnostics to continuous, AI-guided preventive guardrails. They democratize access to early detection and risk stratification by deploying intelligent systems closer to the patient, thereby expanding the clinical funnel. This approach aims to identify conditions earlier, leading to less costly and more effective interventions.
What is the key differentiator for successful AI-native companies in the preventive healthcare space?
The most compelling AI-native companies leverage their technology to move complex diagnostic capabilities into more accessible, lower-cost settings. This not only improves patient outcomes but also creates significant economic efficiencies. Their success also hinges on integrating seamlessly into clinical workflows and navigating regulatory and reimbursement pathways.
How do these AI-native companies ensure clear reimbursement pathways for their services?
These companies secure viable reimbursement pathways by aligning with evolving models and engaging with payers. They aim to establish clear CPT codes and leverage existing frameworks like CMS guidelines for Remote Physiologic Monitoring (RPM) and Remote Therapeutic Monitoring (RTM). By demonstrating that their AI-driven alerts and interventions reduce hospitalizations or adverse events, they align with value-based care models.
Can you provide examples of how AI-native companies are redefining diagnostics?
Caption Health’s AI-powered ultrasound guidance platform enables non-specialized professionals to acquire high-quality cardiac ultrasound images, moving diagnostics to primary care settings. Viz.ai accelerates the identification and triage of critical conditions like stroke, reducing diagnostic delays and improving time-to-treatment. Both examples demonstrate moving complex diagnostics to earlier, lower-cost settings.
